NeoGenomics
↗Fort Myers, USA
NeoGenomics is a leading premier cancer diagnostics and information services company. It operates a network of CAP-accredited and CLIA-certified laboratories across the United States and the United Kingdom, specializing in cancer genetics testing including NGS, IHC, FISH, and flow cytometry.
The company serves oncologists, pathologists, and pharmaceutical firms by providing a comprehensive menu of over 500 oncology-focused tests. NeoGenomics is particularly recognized for its leadership in the community oncology setting, where approximately 80% of cancer care is delivered, and maintains one of the largest oncology databases with over 2 million unique patient profiles.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$727M
Founded:2002
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$200M
Investors:Ranger Investments, K&L Gates, Perella Weinberg Partners
STOCK
Exchange:NASDAQ
Ticker:NEO
Market Cap:$1.3B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:NGS, IHC, FISH, Flow Cytometry, Liquid Biopsy, Cytogenetics
Active Trials:175
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Pathline, LLC, Inivata, Trapelo, Genoptix
Key Partnerships:ConcertAI (AI-driven hematology research), Ultima Genomics (UG 100 sequencing platform), Adaptive Biotechnologies (clonoSEQ integration), PPD (CRO laboratory services integration)
COMPETITION
Position:Leader
Competitors:Quest Diagnostics, Labcorp, Foundation Medicine, Guardant Health, Natera, Exact Sciences
LEADERSHIP
Key Executives:
Tony Zook - CEO
Jeff Sherman - CFO
Warren Stone - President and COO
Scientific Founders:M. Michael Dent
Board Members:Lynn A. Tetrault (Chair), Dr. Marjorie Green, Neil Gunn, Alison L. Hannah
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NeoGenomics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.